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Introduction
Head and neck squamous cell carcinoma (HNSCC) consti-
tutes approximately 3% of all cancer diagnoses in the United 
States, with about 45,000 new cases in 2015 [1]. Among 
head and neck cancers, oral cavity, oropharyngeal, and laryn-
geal cancers are the most common, accounting for 24%, 
23%, and 27% of all diagnosed cases, respectively [2].
Due to the heterogeneity of these subtypes of HNSCC, 
a single prognostic signature identifying high- and low- 
risk patients cannot be generated to cover all types of 
HNSCC. However, multiple studies have indicated that 
individual biomarkers can stratify high- risk and low- risk 
patients within the various subtypes [3–5]. These biomark-
ers are not limited to coding genes. Included among the 
proposed biomarkers are microRNAs (miRNAs), which 
are short single- stranded RNA sequences (~22 n.t.) that 
function in post- transcriptional regulation. Further studies 
have shown that within oropharyngeal cancer, infection 
by human papillomavirus (HPV) is a favorable prognostic 
marker [6]. Greater prognostic power has been attained 
by combining groups of biomarkers into a single signature 
for different subtypes of HNSCC, with various degrees 
of success [7,8].
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Abstract
Identification of novel prognostic biomarkers typically requires a large dataset 
which provides sufficient statistical power for discovery research. To this end, 
we took advantage of the high- throughput data from The Cancer Genome Atlas 
(TCGA) to identify a set of prognostic biomarkers in head and neck squamous 
cell carcinomas (HNSCC) including oropharyngeal squamous cell carcinoma 
(OPSCC) and other subtypes. In this study, we analyzed miRNA- seq data  obtained 
from TCGA patients to identify prognostic biomarkers for OPSCC. The identi-
fied miRNAs were further tested with an independent cohort. miRNA- seq data 
from TCGA was also analyzed to identify prognostic miRNAs in oral cavity 
squamous cell carcinoma (OSCC) and laryngeal squamous cell carcinoma (LSCC). 
Our study identified that miR- 193b- 3p and miR- 455- 5p were positively associ-
ated with survival, and miR- 92a- 3p and miR- 497- 5p were negatively associated 
with survival in OPSCC. A combined expression signature of these four miRNAs 
was prognostic of overall survival in OPSCC, and more importantly, this sig-
nature was validated in an independent OPSCC cohort. Furthermore, we identi-
fied four miRNAs each in OSCC and LSCC that were prognostic of survival, 
and combined signatures were specific for subtypes of HNSCC. A robust 4- miRNA 
prognostic signature in OPSCC, as well as prognostic signatures in other sub-
types of HNSCC, was developed using sequencing data from TCGA as the 
primary source. This demonstrates the power of using TCGA as a potential 
resource to develop prognostic tools for improving individualized patient care.
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The identification of novel biomarkers and subsequent 
development of prognostic signatures requires in- depth 
analysis of genetic profiles. For example, high- throughput 
gene expression profiling data have been made available 
by The Cancer Genome Atlas (TCGA), a joint effort of 
the National Cancer Institute and the National Human 
Genome Research Institute to provide a comprehensive 
set of patient genetic profiles across multiple cancer types 
[9]. This has extended to HNSCC, with a total of 529 
HNSCC samples being made available [10]. Included in 
the available data are RNA- seq and miRNA- seq profiles 
for the majority of the provided patient samples.
In this study, we investigated the prognostic value of 
miRNA biomarkers for oropharyngeal squamous cell car-
cinoma (OPSCC), oral squamous cell carcinoma (OSCC), 
and laryngeal squamous cell carcinoma (LSCC), using 
profiling data obtained from TCGA. These biomarkers 
were then used to develop unique prognostic signatures 
that robustly predicted overall survival in the respective 
subsets of HNSCC. We further demonstrate that use of 
the TCGA public dataset can provide a more general 
picture of head and neck cancer as the prediction models 
obtained can be applied to an independently obtained 
dataset. Through a combined analysis of TCGA data and 
independently generated data, we have provided an addi-
tional set of biomarker tools for the clinical setting that 
can assist in determining the best course of treatment 
for patients with head and neck cancer.
Materials and Methods
Retrieval of public data
A total of 523 anonymized patients in the TCGA database 
were identified as having primary HNSCC. The clinical 
patient files were downloaded from TCGA Data Portal 
(https://tcga-data.nci.nih.gov/tcga/). Of the 523 HNSCC 
patients, 82 patients had a primary tumor in the oro-
pharynx, 313 patients had a primary tumor of the oral 
cavity, and 115 patients had primary tumors in the larynx. 
A cutoff of 5 years was applied to all patient survival 
data.
All gene sequences were downloaded from the UCSC 
Genome Browser [11]. Index files mapping transcript 
accessions to NCBI Gene IDs were downloaded from the 
NCBI ftp site [12]. All mature miRNA sequences were 
downloaded from miRBase [13]. Raw miRNA- seq data 
was obtained for 81 of the 82 OPSCC patients, 311 of 
313 OSCC patients, and all of the laryngeal cancer patients. 
Raw RNA- seq data was obtained for 72 of the 82 
 oropharyngeal cancer patients. All raw RNA- seq and 
miRNA- seq files were downloaded through the Cancer 
Genomics Hub [14].
TCGA sequence analysis
Sequence alignment was performed using the Bowtie pro-
gram [15]. Raw miRNA- seq reads were aligned to the 
human miRNome. The read counts were then normalized 
to reads per million reads mapped per sample and set 
to a floor value of 1 for lowly expressed miRNAs. Raw 
RNA- seq reads were aligned sequentially to human RefSeq 
annotated sequences, the human reference genome, and 
the virome. The read counts were normalized to reads 
per kilobase per million mapped reads, and then to the 
2000th gene before being set to a floor of five normalized 
reads for lowly expressed mRNAs. Both miRNA- seq and 
RNA- seq reads were subsequently log2 normalized.
Statistical analysis for survival and 
correlation
Overall survival analysis was conducted using the “survival” 
package in R (http://www.r-project.org). Correlation and 
covariance analysis was conducted in MATLAB [16]. 
Univariate Cox proportional hazards regression analyses 
were performed to evaluate the correlation between indi-
vidual miRNAs or mRNAs with overall survival. The 
 P- values for outcome correlation were calculated using 
the Wald test. The final prognostic signatures were also 
evaluated in this manner. Multivariate Cox proportional 
hazards analyses were conducted to evaluate the independ-
ent prognostic value of the miRNA signature after con-
trolling for common clinical variables. The Kaplan–Meier 
estimator was used to determine the empirical survival 
probabilities and P- values from the log- rank test indicated 
the significance of the miRNA prediction outcome model.
Collection of independent validation data 
sets
A total of 95 OPSCC cases were included in this study 
for validation. Patients were treated at Washington 
University School of Medicine with definitive chemoradia-
tion, or with primary surgery followed by radiation therapy 
with or without chemotherapy. Clinical data were collected 
from the patients and then updated retrospectively after 
follow- up review.
For all 95 of the patients, formalin- fixed, paraffin- 
embedded (FFPE) tumor tissues were collected for 
pathological analysis before radiotherapy or chemo-
therapy. Sections from each case were stained with 
hematoxylin and eosin, and reviewed by a study patholo-
gist at the Washington University to confirm the diag-
noses. Tumor regions from each section were identified 
and macrodissection was conducted. Total RNA was 
extracted from the identified tumor regions using the 
1621© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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miRNeasy FFPE kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s protocol. In total, 66 patients 
were used for the validation of the OPSCC miRNA 
prognostic model and 39 patients were used for the 
validation of the OPSCC mRNA model.
Quantitative reverse- transcription PCR for 
miRNA model validation
Quantitative reverse- transcription polymerase chain reaction 
(qRT- PCR) was used to profile the miRNAs identified as 
significant in OPSCC. The details of this experimental pro-
cedure have been described previously [17]. Briefly, the RT 
reaction was performed with the High Capacity cDNA 
Reverse Transcription Kit  (Life Technologies, Foster City, 
CA, USA). Each RT reaction included 100 ng of tumor 
RNA and a pool of RT primers for selected miRNAs and 
control RNAs. Quantitative PCR was performed with Power 
SYBR Green PCR Master Mix (Life Technologies) and spe-
cific PCR primers for selected miRNAs or control RNAs. 
miRNA raw profiling data for individual samples were 
normalized with four small RNA controls (SNORD48, 
SNORD47, RNA5- 8S5, and RNU6- 1). Specifically, the expres-
sion levels of the four small RNAs were averaged and used 
as the reference to control for sample variations during 
miRNA profiling analysis.
The expression of p16 protein was determined by 
immunohistochemistry as previously described [18]. The 
expression profiles of E6 and E7 transcripts from six 
oncogenic HPV types were determined by qRT- PCR, 
including types 16, 18, 33, 39, 56, and 59. The details 
of the HPV assays and the experimental protocol have 
been described previously [18]. In brief, primer sequences 
for the assays were selected from the E6 and E7 coding 
regions of the high- risk HPV genomes. The expression 
profiles of GAPDH and β- actin were used as reference 
controls for data normalization.
Results
Validation of an existing miRNA prognostic 
signature
To verify whether the miRNA data obtained from The 
Cancer Genome Atlas (TCGA) could be used in further 
biomarker identification, we evaluated our previously pub-
lished prognostic model for OPSCC [8] with TCGA data. 
Briefly, this model identified miR- 24- 3p, miR- 31- 5p, and 
miR- 193b- 3p as negatively associated with survival, and 
miR- 26b- 5p, miR- 142- 3p, and miR- 146a- 5p as positively 
associated with survival. The expression levels of these 
six miRNAs were then combined to create a single prog-
nostic model as described previously [8]:
We examined each miRNA individually with TCGA data 
and found that two miRNAs were significantly associated with 
survival, two miRNAs maintained borderline significance 
(P < 0.1), and two miRNAs was not found to be significant 
(P > 0.1) (Fig. 1A). It should be noted, however, that the 
directions of expression changes in relation to survival outcome 
were maintained for all six miRNAs (i.e., positive correlations 
for miR- 26b- 5p, miR- 142- 3p, miR- 146a- 5p, and negative cor-
relations for miR- 31- 5p, miR- 193b- 3p, miR- 26b- 5p) (Fig. 1A). 
When we analyzed this prognostic model as whole, it was able 
to significantly differentiate between high- and low- risk OPSCC 
patients from TCGA (Fig. 1B). This demonstrated that this 
previously published model was robust and could be applied 
to patient miRNA profiles obtained from other institutions, 
while also indicating that the data from TCGA was a valuable 













Figure 1. Validation of an existing miRNA signature with TCGA data. 
(A) The six miRNAs from our previously published prognostic model for 
OPSCC were examined for association with the overall survival of TCGA 
patients. Fold change values were log2 transformed and represent the 
average expression difference of the miRNAs in the deceased patient 
group compared to the living patient group. Statistical significance was 
determined with the log- rank test in Cox regression analysis. (B) Kaplan–
Meier survival analysis to evaluate the prognostic performance of the 
six- miRNA signature for predicting overall survival in OPSCC.
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Unique TCGA miRNA expression profiles 
correlated with overall survival in OPSCC
miRNA expression analysis was performed for the 81 
OPSCC patients obtained from TCGA. The characteristics 
of these patients are summarized in Table 1. The miRNAs 
were examined individually using Cox univariate propor-
tional hazards analysis to determine which miRNAs were 
correlated with overall survival. This analysis provides a 
log- rank P- value, which indicates the significance of the 
miRNA in relation to survival, as well as a Wald coef-
ficient, which indicates the weight associated with the 
expression level of the miRNA.
We then implemented recursive feature elimination 
(RFE) technique to determine the relative prognostic per-
formance of individual miRNAs. In this process, a regres-
sion model was generated using the given miRNA features 
and outcomes (i.e., miRNA expression and overall survival, 
respectively), and the least impactful feature was 
eliminated. The process was then repeated until the final 
iteration identified the most significant feature associated 
with the classifier. This was performed on a subset of 
top- ranking 189 miRNAs in OPSCC ordered by log- rank 
P- value while maintaining a Wald coefficient greater than 
or equal to one, and an average expression across all 
samples greater than 1.414 (i.e., a log2 Expression of 0.5). 
In this way, we were able to initially identify a set of 
promising miRNA candidates for further model 
development.
In examining the 50 most significant miRNAs in accord-
ance with the RFE, miR- 193b- 3p, miR- 455- 5p, miR- 92a- 3p, 
and miR- 497- 5p were identified as maintaining a high 
RFE ranking after 10- fold cross- validation, as well as being 
statistically significant in the univariate Cox proportional 
hazards analysis (Fig. 2). All four of these miRNAs have 
been reported as dysregulated in other cancer types, includ-
ing colorectal cancer and pancreatic cancer [19–22]. In 
Table 1. Characteristics of the HNSCC patients included in TCGA.
Characteristics OPSCC (n = 81) OSCC (n = 311) LSCC (n = 115)
Age at diagnosis (mean ± SD, 
years)
55.9 ± 9.3 61.9 ± 13.2 61.9 ± 9.1
Sex
Male 69 (85.2%) 206 (66.2%) 95 (82.6%)
Female 12 (14.8%) 105 (33.8%) 20 (17.4%)
Race
White 75 (92.6%) 268 (86.2%) 91 (79.1%)
Other 6 (7.4%) 43 (13.8%) 24 (20.9%)
Smoking1
Unreported 1 (1.2%) 10 (3.2%) 4 (3.5%)
Nonsmoker 25 (30.8%) 88 (28.3%) 6 (5.2%)
Long- term former smoker 8 (9.9%) 51 (16.4%) 11 (9.6%)
Other former smoker 25 (30.9%) 68 (21.9%) 36 (31.3%)
Current smoker 22 (27.2%) 94 (30.2%) 58 (50.4%)
T classification
T1 13 (16.0%) 29 (9.3%) 7 (6.1%)
T2 36 (44.4%) 102 (32.8%) 20 (17.4%)
T3 20 (24.7%) 64 (20.6%) 33 (28.7%)
T4 12 (14.8%) 116 (37.3%) 55 (47.8%)
N Classification
NX 0 (0.0%) 4 (1.3%) 2 (1.7%)
N0 21 (25.9%) 142 (45.7%) 52 (45.2%)
N1 52 (64.2%) 52 (16.7%) 12 (10.4%)
N2 3 (3.7%) 110 (35.4%) 46 (40.0%)
N3 5 (6.2%) 3 (1.0%) 3 (2.6%)
Stage
I 5 (6.2%) 19 (6.1%) 2 (1.7%)
II 11 (13.6%) 62 (19.9%) 15 (13.0%)
III 12 (14.8%) 57 (18.3%) 18 (15.7%)
IV 53 (65.4%) 173 (55.6%) 80 (69.6%)
Deceased 14 (17.2%) 109 (35.0%) 33 (28.7%)
OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral cavity squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; SD, standard 
deviation.
1Smoking was defined as no history of smoking, a former smoker of ≥15 years, other former smoker of <15 years, or a current smoker.
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particular, the validity of miR- 193b- 3p as a prognostic 
marker in OPSCC was previously reported and incorpo-
rated in our previous model for outcome prediction [8].
A combined miRNA prognostic signature 
predicts overall survival in OPSCC
We further hypothesized that a combination of prognostic 
miRNAs within OPSCC could be effectively used to predict 
overall survival. The miRNAs chosen in the aforementioned 
analysis were used to build the following prognostic model:
where S indicates the risk score for each patient and E 
represents the normalized expression level of the identified 
miRNA from the primary tumor. The coefficients in this 
equation are the Wald scores from the Cox regression 
analysis and are representative of the relative importance 
of the miRNA toward survival status.
In this prediction model, higher scores indicate higher 
risk and predict a poor survival outcome for the patient. 
The patients were stratified internally by median risk score 
to produce two cohorts of similar size, so as to determine 
the validity of the prognostic model. By this method, 40 
OPSCC patients were predicted to be high- risk (with > 
median score) and 41 patients were predicted to be low- risk 
(i.e., with ≤ median score); significantly different risks of 
death were observed based on this classification (P = 6.8E- 
04) (Fig. 3A).
One primary concern for prognostic model development 
is the risk of overtraining. To address this issue, we per-
formed leave- one- out cross- validation. For this cross- 
validation, within each iteration, we removed one sample 
from the training set and trained a model with the miRNA 
profiles from the remaining samples. The removed sample 
was then used for independent model testing. The process 
was repeated until all the samples had been used indepen-
dently for model testing. For each validation round, the 
Wald coefficient for the candidate miRNAs were calculated 
based on the training set and used to generate a slightly 
different model for testing. Cross- validation still yielded a 
significant separation of high- and low- risk patients (Fig. 3B), 












Figure 2. Four significant miRNAs associated with overall survival of TCGA OPSCC patients. Fold change values were log2 transformed and represent 
the average expression difference of the miRNAs in the deceased patient group compared to the living patient group. Significance was determined 
with the log- rank test in Cox regression analysis.
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The miRNA prognostic signature was 
independent of clinical features
We assessed whether the miRNA signature maintained 
its prognostic value within the context of commonly used 
clinical parameters, including age at diagnosis, gender, 
race, smoking history, initial tumor staging, and treat-
ment type. This analysis was conducted through multi-
variate Cox hazards analysis. This miRNA signature was 
found to maintain statistical significance, with a hazards 
ratio of 11.85 and P- value of 3.9E- 03 (Table S1).
The OPSCC miRNA signature maintained its 
prognostic value independent of HPV 
status
Previous work has shown that HPV positivity is a favorable 
prognostic marker in OPSCC, and thus we extended our 
miRNA signature to explore whether the prognostic 
significance was maintained independent of HPV status. 
OPSCC patients were identified as HPV- positive if sequenc-
ing reads from the RNA- seq data that did not align to 
the human genome aligned to any of the 143 types of 
HPV. Of the 72 OPSCC patients with RNA- seq data, 46 
were identified as having reads aligned to one of three 
types of HPV. Specifically, 39 patients were positive for 
HPV16, four for HPV33, and three for HPV35, leaving 
26 patients as HPV- negative.
Of the 46 patients who were identified as HPV- positive, 
35 were identified as low- risk and 11 as high- risk by the 
miRNA prognostic signature. Kaplan–Meier survival analy-
sis indicated that the high- risk group had poor survival 
as compared to the low- risk group (P = 7.9E- 03) (Fig. 3C). 
The model was not statistically significant when applied 
to HPV- negative patients (data not shown); however, it 
should be noted that the HPV- negative set was a much 
smaller cohort (n = 26), which significantly reduced the 
power of the model.
Figure 3. Kaplan–Meier survival analysis to evaluate the novel OPSCC 4- miRNA prognostic signature. Patients were stratified into the low- risk group 
or high- risk group based on risk score. (A) The signature was evaluated for overall survival in the training set from TCGA. Significance was determined 
using the log- rank test. (B) Leave- one- out cross- validation to evaluate the miRNA modeling strategy. The cross- validated results from all rounds were 
combined for prognostic evaluation of overall survival. (C) Independence of the miRNA signature in HPV(+) patients. (D) Survival analysis to evaluate 
the miRNA signature for overall survival in the validation cohort.
A B
C D
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Validation of the OPSCC miRNA signature 
with an independent cohort
To confirm the validity of the 4- miRNA model for OPSCC 
prognosis, we applied our miRNA signature to an inde-
pendent cohort of 66 OPSCC patients treated at the 
Washington University School of Medicine in St. Louis. 
The clinical characteristics of these patients are outlined 
in Table S2. We hypothesized that the miRNA signature 
provides independent prognostic value from HPV bio-
marker. Since HPV positivity is a favorable prognostic 
marker for OPSCC, we were interested to know whether 
the new miRNA signature maintains its prognostic value 
by further risk- stratifying HPV- positive patients.
All 66 patients were preselected to be p16- positive by 
immunohistochemistry, as p16 is a robust surrogate bio-
marker for HPV expression [18]. HPV expression in these 
tumors was further validated by quantitative reverse- 
transcription PCR (qRT- PCR, see Materials and Methods 
for details). Of the 66 tumors, 61 were HPV16- positive 
and two were HPV18- positive. HPV transcripts were not 
detected in the remaining three samples.
Furthermore, qRT- PCR was conducted on the tumor 
samples for the four miRNAs included in the signature. 
miRNA expression readings were normalized using four 
internal small RNA controls (see Materials and Methods 
for details). The risk score was then calculated for each 
of these patients based on the miRNA signature. The 
patients were then stratified into high- risk and low- risk 
groups by the median risk score. Kaplan–Meier survival 
analysis indicated that the miRNA model was significantly 
predictive of survival outcome for the 63 HPV- positive 
cases (P = 1.6E- 03, Fig. 3D). The miRNA signature had 
a similar prognostic performance when applied to all 66 
p16- positive cases (P = 2.8E- 03).
We also analyzed the signature prediction scores with 
a receiver operating characteristic curve, which evaluated 
both the true positive rate (sensitivity) and the false posi-
tive rate (specificity). In the training and validation sets, 
the areas under the curve were 0.84 and 0.84, respectively, 
indicating robust performance of the model for both 
sensitivity and specificity when applied to independent 
cohorts (Figure S1).
Figure 4. Kaplan–Meier survival analysis to evaluate the OSCC and LSCC miRNA prognostic models. (A, B) The models were evaluated in the 
respective training sets. (C, D) Leave- one- out cross- validation results were combined for prognostic evaluation.
A B
C D
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Unique miRNA expression profiles 
correlated with distinct subtypes of head 
and neck cancer
We extended our miRNA expression profiling analysis to 
the 311 OSCC and 115 LSCC patients obtained from 
TCGA. The characteristics of these patients are summarized 
in Table 1. For each additional subtype of HNSCC, we 
conducted similar analyses as described for OPSCC and 
identified four miRNAs in each subset that were predictive 
of overall survival (Table S5). These miRNAs were then 
combined to generate the following prognostic models:
As described earlier, the median score was used within 
each subset to separate patients into high- and low- risk 
groups, which were also found to have significantly dif-
ferent risks of death (P = 1.8E- 04 in OSCC and P = 2.4E- 
03 for LSCC) (Fig. 4A and B). We also conducted 
leave- one- out cross- validation analysis for these two sig-
natures and found a significantly different risk of survival 
in the miRNA- stratified groups of OSCC and a borderline 
significance for LSCC (Fig. 4C and D). Despite borderline 
significance of the LSCC model in cross- validation analysis, 
the LSCC prognostic miRNA model may still be useful 
for prediction of patient survival. In particular, these models 
maintained statistical significance independent of clinical 
features when analyzed with multivariate Cox analysis, with 
the OSCC model having a hazards ratio of 1.88 and a 
P- value of 1.8E- 03, and the LSCC model having a hazards 
ratio of 2.84 and a P- value of 1.3E- 02 (Table S1).
It is noteworthy that each miRNA signature carried 
prognostic significance when applied to the HNSCC sub-
type where it was derived. On the other hand, when 
applied to other subtypes of HNSCC, none of the sig-
natures were able to effectively distinguish high- risk and 
low- risk patients (Figure S2). We also observed this phe-
nomenon when we applied the previously developed 
6- miRNA prognostic model to OSCC and LSCC (Figure 
S3). In conjunction with previous studies indicating sig-
nificant genetic heterogeneity between subtypes of HNSCC 
[10], our results indicate that the miRNome is just as 
unique for each HNSCC subtype.
Discussion
Identification of novel prognostic biomarkers typically 
requires a large dataset, which provides sufficient statistical 
power for discovery research. To this end, we took advan-
tage of the high- throughput data from TCGA for biomarker 
analysis. The TCGA consortium has published many studies 
identifying the mutations and dysregulations associated 
with tumors in comparison to matched normal tissue 
samples. There are also a number of studies that used 
TCGA data for independent validation of existing bio-
markers [23–25]. Additionally, many studies exploring 
miRNA biomarkers in head and neck cancer, such as the 
miR- 34 family and miR- 200a, have indicated their roles 
in oncogenesis [26]. However, few studies have utilized 
TCGA data in systematically identifying biomarkers associ-
ated with patient outcome.
In this study, we have presented a new strategy to 
identify prognostic miRNA biomarkers by analyzing TCGA 
data directly, followed by experimental validation using 
an independent cohort. As the first step, we utilized TCGA 
data as the primary source to identify biomarkers and 
develop prognostic models for OPSCC. Within OPSCC, 
infection by HPV has already been indicated as a favorable 
prognostic factor [6]. Our model was able to further 
improve the prognostic value of HPV positivity by iden-
tifying a high- risk cohort among HPV(+) patients. Next, 
we were able to validate the robustness of this signature 
using an independent cohort that consisted only of HPV(+) 
OPSCC patients. This confirmed that the miRNA signature 
was able to further distinguish high- and low- risk patients 
within HPV(+) OPSCC patients.
Among the subtypes of HNSCC, OPSCC has unique 
characteristics as HPV infection is associated with most 
OPSCC cases. Although the total number of HNSCC cases 
has decreased steadily on a yearly basis, the number of 
reported OPSCC cases has increased significantly as a 
result of rapid rise in HPV(+) OPSCC cases [27,28]. Our 
clinical goal of building a powerful prognostic model is 
to reliably stratify OPSCC patients for treatment failures 
after standard therapy. The availability of such a reliable 
prognostic model is critical for providing individualized 
cancer therapy, including both deintensifying treatment 
for low- risk patients as well as intensification for high- risk 
patients. In particular, there is currently significant clinical 
interest in identifying a subset of OPSCC patients who 
have low- risk of treatment failures, in order to deintensify 
their overall treatment. As present, multi- institutional de- 
escalation clinical trials are underway for HPV(+) OPSCC 
patients [29,30]. However, there is still a significant por-
tion of HPV(+) OPSCC cases that have poor outcome. 
For these cases, de- escalation treatment should not be 
applied and instead the treatment should be intensified. 
Thus, there is a critical need to develop robust prognostic 
models to further stratify HPV(+) OPSCC patients for 
enrollment in de- escalation trials. To this end, our pro-
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need by selecting HPV(+) OPSCC patients who will most 
likely benefit from de- escalation treatment. Further work 
would be required to bring this signature fully to the 
clinical setting, such as the inclusion of robust reference 
genes to standardize the signature scores, which allows 
clinicians to determine the appropriate treatment modality 
based a predefined threshold score.
Besides OPSCC, we have also shown that our strategy 
on TCGA- based biomarker discovery can be extended to 
the study of other subtypes of HNSCC. In this way, we 
have demonstrated that TCGA represents a rich resource 
for cancer prognostic studies. We expect that prognostic 
tools developed using TCGA data, with proper validation, 
will significantly expand our ability to more precisely 
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